Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis

Int J Tuberc Lung Dis. 2012 Feb;16(2):221-3, i-ii. doi: 10.5588/ijtld.11.0266.

Abstract

In a study performed in Cambodia, a higher number of tuberculosis (TB) strains with mutations in the pncA gene associated with pyrazinamide resistance (PZA-R) was found in fluoroquinolone-resistant (FQ-R) multidrug-resistant (MDR) strains (93%), compared with 47% in MDR and 3% in non-MDR strains. This emphasises the need for easy and rapid tests for identification of PZA-R for efficient treatment of MDR-TB.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amidohydrolases / genetics*
  • Antitubercular Agents / therapeutic use
  • Cambodia / epidemiology
  • DNA, Bacterial / genetics*
  • Fluoroquinolones / therapeutic use*
  • Genotype
  • Humans
  • Incidence
  • Mutation*
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / genetics*
  • Mycobacterium tuberculosis / isolation & purification
  • Pyrazinamide / therapeutic use*
  • Retrospective Studies
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / epidemiology
  • Tuberculosis, Multidrug-Resistant / microbiology

Substances

  • Antitubercular Agents
  • DNA, Bacterial
  • Fluoroquinolones
  • Pyrazinamide
  • Amidohydrolases
  • PncA protein, Mycobacterium tuberculosis